2024 年第 11 期 第 19 卷

利福平与利福喷丁在老年肺结核治疗中的临床效果比较

Comparison of clinical effects of rifampicin and rifapentine in the treatment of elderly patients with pulmonary tuberculosis

作者：王丽洁1周光闹2何媚燕2

英文作者：Wang Lijie1 Zhou Guangnao2 He Meiyan2

单位：1浙江中医药大学附属丽水中医院浙江省丽水市中医院药剂科，丽水323000；2浙江中医药大学附属丽水中医院浙江省丽水市中医院结核科，丽水323000

英文单位：1Department of Pharmacy Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Lishui 323000 China; 2Department of Tuberculosis Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Lishui 323000 China

关键词：老年肺结核；利福平；利福喷丁

英文关键词：Pulmonarytuberculosisintheelderly;Rifampicin;Rifapentine

• 摘要：

• 目的 对比利福平与利福喷丁在老年肺结核治疗中的临床效果。方法 回顾性收集2020年1月至2022年12月就诊于浙江中医药大学附属丽水中医院结核科的218例老年肺结核患者的临床资料进行分析，按照应用药物不同分为利福平组（109例）和利福喷丁组（109例）。2组患者均接受常规抗结核治疗，利福平组患者在常规治疗基础上加用利福平，利福喷丁组患者在常规治疗基础上加用利福喷丁。疗程均为6～12个月。比较2组患者的临床基线资料、不良反应发生情况、服药依从性、疗效。结果 2组患者临床基线资料比较，差异均无统计学意义(均P＞0.05)。利福平组不良反应发生率高于利福喷丁组［17.4%（19/109）比8.2%（9/109）］，差异有统计学意义(χ2=4.098,P＝0.043)。利福平组Morisky用药依从性量表评分高于利福喷丁组，差异有统计学意义(P<0.05)。利福平组治疗成功率高于利福喷丁组，但差异无统计学意义(P>0.05)。结论 利福喷丁与利福平在治疗老年肺结核中效果相当且具有较高安全性,在老年肺结核抗结核方案选择上可应用利福喷丁替代利福平。

• Objective To compare the clinical effect of rifampicin and rifapentine in the treatment of elderly patients with pulmonary tuberculosis. Methods The clinical data of 218 elderly patients with pulmonary tuberculosis admitted to the Department of Tuberculosis, Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University from January 2020 to December 2022 were retrospectively collected and analyzed. Patients were divided into rifampicin group (109 cases) and rifapentine group (109 cases) according to different drugs. Both groups received conventional anti-tuberculosis treatment. The patients in the rifampicin group were treated with rifampicin on the basis of conventional treatment, and the patients in the rifapentine group were treated with rifapentine on the basis of conventional treatment. All patients were treated for 6 to 12 months. The clinical baseline data, adverse reactions, medication compliance and efficacy were compared between the two groups. Results There were no significant differences in clinical baseline data between the two groups (all P>0.05). The incidence of adverse reactions in rifampicin group was higher than that in rifapentine group ［17.4%(19/109) vs 8.2%(9/109)］(χ2=4.098, P=0.043). The Morisky medication adherence scale score of the rifampicin group was higher than that of the rifapentine group (P<0.05). The success rate of rifampicin group was higher than that of rifapentine group (P>0.05). Conclusion Rifapentine and rifampicin have similar efficacy in the treatment of elderly pulmonary tuberculosis, and with high safety. Rifapentine can be used instead of rifampicin in the selection of anti-tuberculosis regimens for elderly pulmonary tuberculosis.